Moin Saleem | Founder & CSA
Purespring Therapeutics

Professor Saleem trained as an undergraduate at University College, London. Paediatric nephrology training at Great Ormond Street Hospital, London. He set up his independent laboratory programme in glomerular cell biology in Bristol, as well as holding a post as a consultant paediatric nephrologist since 1999, with an international reputation in management of nephrotic syndromes, and a pioneer of the field of podocyte biology. He heads Bristol Renal, a glomerular research group of approximately 45 researchers, covering all areas from cell biology, transgenic models and population cohorts and genetics (H index 86). He was the originator of the UK Renal Rare Disease Registry (RaDaR), and currently leads the UK nephrotic syndrome study (NephroS), as well as a major industry-academic collaboration termed NURTuRE (National Unified Renal Translational Research Enterprise). He is PI on several MRC projects, including Precision Medicine, laboratory project grants and a Global Challenges program to establish international NS cohorts. His gene therapy program commenced in 2014, and is focused on targeting the podocyte in order to radically change the treatment of kidney diseases. He is co-Founder and Chief Scientific Advisor of Purespring Therapeutics, with first in man clinical trials now in progress.